Litcius/Paper detail

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

Noura J. Choudhury, Antonio Marra, Jane Sze Yin Sui, Jessica Flynn, Soo‐Ryum Yang, Christina J. Falcon, Pier Selenica, Adam J. Schoenfeld, Natasha Rekhtman, Daniel R. Gomez, Michael F. Berger, Marc Ladanyi, Maria E. Arcila, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Glenn Heller, Jorge S. Reis‐Filho, Helena A. Yu

2022Journal of Thoracic Oncology96 citationsDOIOpen Access PDF

Topics & Concepts

OsimertinibMedicineAcquired resistanceMutantDiseaseLung cancerFirst lineLung diseaseOncologyLungCancer researchInternal medicineEpidermal growth factor receptorCancerGeneticsGeneBiologyErlotinibLung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers | Litcius